- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alberto Ascherio Discusses Vitamin D and MS
Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the role of vitamin D insufficiency in the risk of multiple sclerosis (MS) and the optimal dose of vitamin D for patients with MS.
Alberto Ascherio, MD, DrPh, professor of epidemiology and nutrition at the Harvard T. H. Chan School of Public Health and professor of medicine at the Harvard Medical School, discusses the role of vitamin D insufficiency in the risk of multiple sclerosis (MS) and the optimal dose of vitamin D for patients with MS.
Transcript
What role does vitamin D insufficiency have in MS risk, and has an optimal vitamin D dose been established?
Individuals with low vitamin D levels have a higher risk of MS. It’s about a two-fold higher risk in people who are vitamin D deficient as compared to people with optimal levels. It has not been determined in a final way, but I think it's pretty reasonable to think about 3000, around 3000 iu per day of oral vitamin D3 would probably be sufficient for the large majority of patients. It’s a dose that would increase the level of vitamin D from a median of 50 nmol/L, which is what we find the European patient with MS, to close to 100 nmol/L, which is the level that you find associated with optimal outcome in MS.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More
